NCT07001150CompletedPhase 2
Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 23 May 2025
- Start date
- 10 May 2025
- Primary completion date
- 30 May 2026
- Lead sponsor
- Tanta University
- Diseases
- Parkinson disease
- NCT number
- NCT07001150
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 50
- From 10 May 2025 to the primary completion date, 30 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Suspected hypersensitivity to silymarin or multivitamins
- Advanced liver disease (e.g., ascites, bleeding esophageal varices, and hepatic encephalopathy)
- Other conditions, which, in the opinion of the investigators, make the patient unsuitable for enrollment.
Lab values
- Subjects with severe illness, e.g., multisystem failure, cancer, or poorly controlled diabetes, i.e., known diabetic with Hemoglobin A1C (HbA1C)\>7%
Age
- Subjects \< 18 years of age
Other
- Pregnant or breastfeeding women
- Subjects with morbid obesity, i.e., a Body Mass Index (BMI) \> 40
- Current use of Silymarin or recent use within the past two weeks.
Who the study is looking for
- Age between 45 and 65 years old
- Both sexes
- Patients with Parkinson's disease on dopamine replacement therapy
- Modified Hoehn and Yahr stage, MHY 1-4 (29)
Age in the registry: 45 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta Hospital for Mental Health Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.